🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07676084
Recruiting Phase 4

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

NCT07676084 · tracked via the Priya Life Science USA tracker
Sponsor
Andover Research Eye Institute
Phase
Phase 4
Started
2026-06-03
Last updated
2026-06-30

Condition(s) studied

Dry Eye Disease (DED)

Investigational drug(s) / intervention(s)

Preservative Free Polyethylene glycol 400 0.25%Propylene Glycol (0.6%)Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%

Preservative Free Polyethylene glycol 400 0.25%: 4 times daily \[QID\]

Propylene Glycol (0.6%): Preservative Free Propylene Glycol (0.6%)

Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%: QID Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%

Study summary

A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Be at least 18 years of age, male or female 2. Able to provide written voluntary informed consent 3. Able and willing to adhere to the protocol instructions, including participation in all study visits 4. Subject-reported symptoms or history consistent with dry eye for at least 6 months prior to Screening/Baseline (Visit 1) 5. Ocular Surface Disease Index (OSDI) score \>13 Exclusion Criteria: Note: All ocular exclusion criteria apply to either eye. 1. DED secondary to destruction of conjunctival goblet cells due to ocular trauma (eg, alkali burns) or ocular or systemic condition (eg, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, Vitamin A deficiency) 2. Any abnormal lid or corneal anatomy that would interfere with eyelid closure or create an irregular ocular tear film 3. Any active ocular infection, inflammation, or ocular allergy 4. Have undergone ocular surgery or laser refractive surgery within 9 months prior to Screening/Baseline (Visit 1) 5. Use of LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands within 6 months prior to Screening/Baseline (Visit 1) 6. Occlusion of the ocular puncta within 30 days prior to Screening/Baseline (Visit 1) 7. Have worn contact lenses within 3 days prior to Screening/Baseline (Visit 1) or planned wear during the study 8. Use of topical prescription products for dry eye, including topical ocular anti inflammatories (eg, cyclosporine, lifitegrast), corticosteroids, MIEBO® (perfluorohexyloctane ophthalmic solution), or TRYPTYR® (alcotremon ophthalmic solution) within 30 days prior to Screening/ Baseline (Visit 1) 9. Use of any eye drops (prescription or OTC, such as artificial tears or Lumify®) and/or TrueTear™ device (intranasal tear neurostimulator) within 24 hours prior to Screening/ Baseline (Visit 1) 10. Changes in any systemic medications known to impact tear production (eg, antihistamines, antidepressants, hormone replacement therapy, etc.) within 3 months prior to Screening/Baseline (Visit 1) 11. Have a serious or uncontrolled systemic disease (eg, diabetes, rheumatoid arthritis, lupus, hypertension, malignancy) that, in the opinion of the Investigator, will interfere with the study or interpretation of study results

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Andover Eye Associates Andover Massachusetts Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07676084 on ClinicalTrials.gov ↗ ← All trials in the USA